| Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent KM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ... Journal of medicinal chemistry 61 (22), 9889-9907, 2018 | 232 | 2018 |
| First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors DSP Tan, J de Bono, A Caldwell, R, Terbuch, BC Goh, V Heong, N Haris, ... Asian Society of Gynecologic Oncology - 6th Biennial Meeting, 2019 | 165 | 2019 |
| First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due … S Postel-Vinay, K Herbschleb, C Massard, V Woodcock, JC Soria, ... European Journal of Cancer 109, 103-110, 2019 | 101 | 2019 |
| Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent GP Wilkinson, JP Taylor, S Shnyder, P Cooper, PW Howard, DE Thurston, ... Investigational New Drugs 22, 231-240, 2004 | 82 | 2004 |
| Drug–drug interaction potential of darolutamide: in vitro and clinical studies C Zurth, M Koskinen, R Fricke, O Prien, T Korjamo, K Graudenz, K Denner, ... European Journal of Drug Metabolism and Pharmacokinetics 44, 747-759, 2019 | 72 | 2019 |
| Pharmacokinetics, metabolism & glutathione reactivity of SJG-136 GP Wilkinson, PM Loadman, TC Jenkins, J Taylor, SD Shnyder, ... BRITISH JOURNAL OF CANCER 88 (Br J Cancer 88: S25-S54; doi:10.1038/sj.bjc …, 2003 | 58 | 2003 |
| Pharmacokinetic and intracellular pharmacological characteristics of the novel pyrrolobenzodiazepine (PBD) dimer SJG-136 GP Wilkinson, P Loadman, J Taylor, TC Jenkins, D Swaine, JA Double, ... Proceeding of the American Association for Cancer Research 44, 1634-, 2003 | 58 | 2003 |
| Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results M Heuser, N Palmisiano, I Mantzaris, A Mims, C DiNardo, LR Silverman, ... Leukemia 34 (11), 2903-2913, 2020 | 46 | 2020 |
| Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients CD Jones, K Blades, KM Foote, SM Guichard, PJ Jewsbury, T McGuire, ... Abstracts of the AACR Annual Meeting; 2013/04; Washington, DC, Abstract nr 2348, 2013 | 42 | 2013 |
| First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JS De Bono, DSP Tan, R Caldwell, A Terbuch, BC Goh, V Heong, ... Journal of Clinical Oncology 37 (15_suppl), 3007-3007, 2019 | 32 | 2019 |
| First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies S Postel-Vinay, K Herbschleb, C Massard, V Woodcock, M Ocker, ... European Journal of Cancer 69, S7-S8, 2016 | 19 | 2016 |
| Discovery of a series of 2-(pyridinyl) pyrimidines as potent antagonists of GPR40 MJ Waring, DJ Baker, SNL Bennett, AG Dossetter, M Fenwick, R Garcia, ... MedChemComm 6 (6), 1024-1029, 2015 | 15 | 2015 |
| Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition … A Schneeweiss, D Hess, M Joerger, A ,Varga, S Moulder, ... Cancers 11 (12), 1987, 2019 | 14 | 2019 |
| Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes DJ Baker, GP Wilkinson, AM Atkinson, HB Jones, M Coghlan, AD Charles, ... British Journal of Pharmacology 171 (7), 1642–1654, 2014 | 13 | 2014 |
| Characterisation of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes DJ Baker, AM Atkinson, GP Wilkinson, GJ Coope, AD Charles, B Leighton British Journal of Pharmacology 171 (7), 1629–1641, 2014 | 13 | 2014 |
| Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with … TA Yap, DS Tan, A Stathis, GI Shapiro, S Iwasa, M Joerger, J Zhang, ... Cancer Research 82 (12_Supplement), CT006-CT006, 2022 | 12 | 2022 |
| Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies. C Zurth, K Graudenz, K Denner, T Korjamo, R Fricke, G Wilkinson, F Seitz, ... Journal of Clinical Oncology 37 (7_suppl), 297-297, 2019 | 9 | 2019 |
| Open access liquid chromatography/tandem mass spectrometry: Implementation of a fully quantitative system in a drug discovery laboratory JG Swales, G Wilkinson, R Gallagher, C Hammond, C O’Donnell, R Peter International Journal of High Throughput Screening, 1-14, 2010 | 9 | 2010 |
| Matched triplicate design sets in the optimisation of glucokinase activators-maximising medicinal chemistry information content MJ Waring, SNL Bennett, S Boyd, L Campbell, RDM Davies, S Gerhardt, ... MedChemComm 4 (4), 657-662, 2013 | 8 | 2013 |
| Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets–the discovery of AZD3651 and AZD9485 MJ Waring, SNL Bennett, S Boyd, L Campbell, RDM Davies, ... MedChemComm 4 (4), 663-668, 2013 | 8 | 2013 |
